Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

202.47 -0.61 (-0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,358,187
Open 203.01
Bid (Size) 202.00 (1)
Ask (Size) 202.47 (8)
Prev. Close 203.08
Today's Range 201.77 - 204.41
52wk Range 105.43 - 204.41
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
It's Not Tesla, Meta Or Nvidia — The Best Performing Large-Cap Stock In 2023 Is A Crypto Play
The SPDR S&P 500 ETF Trust (NYSE: SPY) has seen a positive return in 2023. Several sectors are in the green so far this year, and many well-known stocks are among the biggest gainers. Here’s a look at... 
Via Benzinga

Performance

YTD
+57.32%
+57.32%
1 Month
+13.32%
+13.32%
3 Month
+57.32%
+57.32%
6 Month
+47.04%
+47.04%
1 Year
+35.99%
+35.99%

More News

Read More
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
3 Low P/E Stocks That Are Bound to Rebound This Year
Via InvestorPlace
Analyst Ratings for Seagen
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Via The Motley Fool
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Via MarketBeat
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
Via The Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
Via The Motley Fool
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Via Talk Markets
MarketBeat Week in Review – 3/13 - 3/17
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
Via Investor's Business Daily
This Must-Buy Dividend Growth Stock Could Pay You for Life
Via The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Via MarketBeat
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023
Via Benzinga
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Via Benzinga
Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Does This Billion-Dollar Deal Solve Pfizer's Biggest Problem?
Via The Motley Fool
Key Inflation Meter Doesn't Show New Signs for Concern and Stocks Begin Shaking Off Instability
Via Benzinga
Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.